CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		53 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenue
Diagnostic testing service	$ 72,187	$ 104,011	$ 361,905	$ 376,696	$ 837,307
Product sales	4,410	1,565	223,440	6,690	231,380
Total Revenue	76,597	105,576	585,345	383,386	1,068,687
Cost of Revenue
Diagnostic testing service	25,938	9,000	75,893	29,985	111,638
Product sales	0	0	238,669	0	243,833
Total Cost of Revenue	25,938	9,000	314,562	29,985	355,471
Loss on reduction of inventory to LCM	0	6,077	0	29,884	121,910
Gross Profit	50,659	90,499	270,783	323,517	591,306
Selling expenses	373,418	87,704	965,383	281,971	1,605,259
Research and development expenses	321,111	548,108	731,258	1,508,944	4,288,644
General and administrative expenses	2,858,027	590,359	6,600,819	1,896,254	12,423,155
Total operating expenses	3,552,556	1,226,171	8,297,460	3,687,169	18,317,058
Operating Loss	(3,501,897)	(1,135,672)	(8,026,677)	(3,363,652)	(17,725,752)
Interest income	53	46	53	1,219	6,641
Interest expense	1	7,756	360	11,816	39,531
Net Loss before Income Taxes	(3,501,845)	(1,143,382)	(8,026,984)	(3,374,249)	(17,758,642)
Income Taxes	0	0	0	0	250
Net Loss	$ (3,501,845)	$ (1,143,382)	$ (8,026,984)	$ (3,374,249)	$ (17,758,892)
Loss per common share - basic and diluted (in dollars per share)	$ (0.22)	$ (0.10)	$ (0.55)	$ (0.30)	$ (1.95)
Weighted average shares outstanding, basic & diluted (in shares)	15,830,033	11,256,867	14,697,221	11,256,867	9,127,656